• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Stryker (SYK) Could Be 6% Undervalued Following Its Outlook Cut

    Simply Wall St·11/01/2026 00:34:10
    语音播报

    Stryker (SYK) cut its 2026 outlook after third quarter results came in below expectations, citing weaker hip and knee procedure volumes, supply issues in peripheral vascular products, capital equipment execution challenges, and a sizeable goodwill impairment.

    The weaker quarter and reduced outlook hit sentiment hard. Stryker’s share price dropped 6.4% in the last session and is down 16.2% year to date. The 1 year total shareholder return has fallen 17.2%, even though the 3 and 5 year total shareholder returns remain positive.

    Scan how Stryker compares with other medical tech players facing similar pressure on expectations by reviewing list of solid balance sheet and fundamentals (25 results) in the same sector.

    Stryker now trades well below both its recent high and the average analyst target near US$342, with intrinsic value estimates implying an even wider gap. Where does fair value actually sit after this reset in expectations?

    Most Popular Narrative: 6% Undervalued

    Stryker’s most followed valuation story points to a fair value of $311.21, which sits above the recent close at $291.86 and frames the latest pullback as an opportunity in the eyes of that thesis author.

    Stryker is my defensive-growth anchor, a high-quality medtech leader in orthopaedics, surgical equipment and MedSurg, riding the durable tailwind of an ageing population. Demographics, not hype, drive this thesis.

    Catalysts include the Mako robotic-surgery platform expanding its installed base (and recurring revenue), steady procedure volumes, and disciplined bolt-on M&A. Recurring consumables make the model sticky.

    See why 6 investors see Stryker as 6% undervalued.

    According to duarte_EM, the narrative applies a discount rate of 7.68% and lands on that $311.21 fair value, which implies Stryker trades at about a 6% discount to this estimate after the recent selloff. The thesis hinges on Stryker’s exposure to ageing demographics, recurring consumables and the Mako robotic surgery platform, which together underpin the cash flow profile used in the valuation.

    That narrative also frames Stryker as a “defensive-growth anchor” rather than a deep value idea, meaning the perceived upside comes from compounding earnings and maintaining a quality premium rather than a quick rerating. For context, Simply Wall St’s own discounted cash flow work currently estimates Stryker’s future cash flow value at $400.05, which also suggests the share price is below an internally assessed fair value based on projected cash generation.

    Result: Fair Value of $311.21 (UNDERVALUED)

    Still, the thesis can crack if hospital capital spending stays weak or if Stryker struggles to integrate acquisitions cleanly after this reset in guidance.

    Find out about the key risks to this Stryker narrative.

    Next Steps

    If that mix of concerns and potential upside around Stryker leaves you split, move fast, dig into the details, and weigh the trade offs yourself. To see how the current data stacks up on both sides, review the 4 key rewards and 2 important warning signs

    Looking for more investment ideas beyond Stryker?

    You have seen how one reset in expectations can change the story for Stryker. Do not stop there. Broaden your watchlist and let the data work for you.